- Home
- PLX vs ALXO Comparison
PLX vs ALXO Comparison
Compare PLX & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | ALXO |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 205.9M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLX | ALXO |
|---|---|---|
| Price | $2.67 | $2.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $3.50 |
| AVG Volume (30 Days) | 757.1K | ★ 1.0M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $1.02 |
| 52 Week High | $3.19 | $2.66 |
Technical Indicators
Market Signals| Indicator | PLX | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 50.59 |
| Support Level | $2.59 | $1.90 |
| Resistance Level | $2.71 | $2.17 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 87.78 | 47.92 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.